Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain

Androgen receptor (AR) is a validated drug target for all stages of prostate cancer including metastatic castration-resistant prostate cancer (CRPC). All current hormone therapies for CRPC target the C-terminal ligand-binding domain of AR and ultimately all fail with resumed AR transcriptional activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Banuelos, Carmen A., Tavakoli, Iran, Tien, Amy H., Caley, Daniel P., Mawji, Nasrin R., Li, Zhenzhen, Wang, Jun, Yang, Yu Chi, Imamura, Yusuke, Yan, Luping, Wen, Jian Guo, Andersen, Raymond J., Sadar, Marianne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2016
Materias:
Gene Regulation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064002/
https://www.ncbi.nlm.nih.gov/pubmed/27576691
http://dx.doi.org/10.1074/jbc.M116.734475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064002/
https://www.ncbi.nlm.nih.gov/pubmed/27576691
http://dx.doi.org/10.1074/jbc.M116.734475

Ejemplares similares